Cargando…
Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy
BACKGROUND: There is growing evidence that antibody responses play a role in the resolution of SARS-CoV-2 infection. Patients with primary or secondary antibody deficiency are at increased risk of persistent infection. This challenging clinical scenario is associated with adverse patient outcome and...
Autores principales: | Taha, Yusri, Wardle, Hayley, Evans, Adam B., Hunter, Ewan R., Marr, Helen, Osborne, Wendy, Bashton, Matthew, Smith, Darren, Burton-Fanning, Shirelle, Schmid, Matthias L., Duncan, Christopher J. A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8717300/ https://www.ncbi.nlm.nih.gov/pubmed/34969393 http://dx.doi.org/10.1186/s12941-021-00491-2 |
Ejemplares similares
-
Casirivimab-Imdevimab (REGN-COV2) for Mild to Moderate SARS-CoV-2 Infection in Kidney Transplant Recipients
por: Liu, Esther C., et al.
Publicado: (2021) -
Treatment of COVID-19 with monoclonal antibodies casirivimab and imdevimab in pregnancy
por: Folkman, Rebecca, et al.
Publicado: (2022) -
Casirivimab/Imdevimab: First Approval
por: Deeks, Emma D.
Publicado: (2021) -
Casirivimab and imdevimab for COVID-19
Publicado: (2022) -
French pharmacovigilance survey of casirivimab - imdevimab monoclonal antibodies in coronavirus disease (COVID-19)
por: de Canecaude, Claire, et al.
Publicado: (2023)